Anti-platelet aggregating agents

Ticlopidine (Figure 7.3), another substituted thiophene that is clinically utilized as an anti-platelet aggregation agent, is reportedly the first selective mechanism-based inactivator of CYP2C19 . This inactivation apparently occurs during S-oxidation of the thiophene moiety. The failure of GSH (5 mM) to inhibit ticlopidine-mediated... 

CysNO is a potent anti-platelet agent Like other nitrosothiols, it increased the intracellular GMP level in platelets in vitro and inhibited collagen-induced platelet aggregation and ADP-induced activation of GP Ilb/IIIa on the platelet surface [45, 47]. However its potency to release NO, stimulate platelet soluble GS and elevate intracellular platelet cGMP was higher than of GSNO [47, 72]. 

Arterial thrombi (white thrombi) are formed initially from both platelets and fibrin in medium-sized arteries on the basis of atherosclerosis. These thrombi can lead to symptoms of, among others, myocardial ischemia and myocardial infarction. The treatment is primarily aimed at prevention of thrombus formation with platelet aggregation inhibitors. For the treatment of myocardial infarction thrombolytic agents are used and for secondary prevention both oral anticoagulants and anti-platelet drugs are employed. 

Folie BJ, Mclntire LV, Lasslo A (1988) Effects of a novel antiplatelet agent in mural thrombogenesis on collagen-coated glass. Blood 72 1393-1400 Konstantopolous K, Kamat SG, Schafer Al et al. (1995) Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein Ilb/IIIa antibody fragment,... 

---